Literature DB >> 24405087

Advances in understanding the leukaemia microenvironment.

Yoko Tabe1, Marina Konopleva.   

Abstract

Dynamic interactions between leukaemic cells and cells of the bone marrow are a feature of haematological malignancies. Two distinct microenvironmental niches in the bone marrow, the 'osteoblastic (endosteal)' and 'vascular' niches, provide a sanctuary for subpopulations of leukaemic cells to evade chemotherapy-induced death and allow acquisition of drug resistance. Key components of the bone marrow microenvironment as a home for normal haematopoietic stem cells and the leukaemia stem cell niches, and the molecular pathways critical for microenvironment/leukaemia interactions via cytokines, chemokines and adhesion molecules as well as hypoxic conditions, are described in this review. Finally, the genetic abnormalities of leukaemia-associated stroma are discussed. Further understanding of the contribution of the bone marrow niche to the process of leukaemogenesis may provide new targets that allow destruction of leukaemia stem cells without adversely affecting normal stem cell self-renewal.
© 2014 John Wiley & Sons Ltd.

Entities:  

Keywords:  bone marrow microenvironment; leukaemia; stem cell niche

Mesh:

Year:  2014        PMID: 24405087      PMCID: PMC4381431          DOI: 10.1111/bjh.12725

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  104 in total

1.  Signals from the sympathetic nervous system regulate hematopoietic stem cell egress from bone marrow.

Authors:  Yoshio Katayama; Michela Battista; Wei-Ming Kao; Andrés Hidalgo; Anna J Peired; Steven A Thomas; Paul S Frenette
Journal:  Cell       Date:  2006-01-27       Impact factor: 41.582

Review 2.  Stromal abnormalities in neoplastic bone marrow diseases.

Authors:  U Dührsen; D K Hossfeld
Journal:  Ann Hematol       Date:  1996-08       Impact factor: 3.673

3.  Tumor-associated macrophages regulate tumorigenicity and anticancer drug responses of cancer stem/initiating cells.

Authors:  Masahisa Jinushi; Shigeki Chiba; Hironori Yoshiyama; Kenkichi Masutomi; Ichiro Kinoshita; Hirotoshi Dosaka-Akita; Hideo Yagita; Akinori Takaoka; Hideaki Tahara
Journal:  Proc Natl Acad Sci U S A       Date:  2011-07-11       Impact factor: 11.205

4.  Adhesion to fibronectin via alpha4 integrin (CD49d) protects B cells from apoptosis induced by serum deprivation but not via IgM or Fas/Apo-1 receptors.

Authors:  M Garcia-Gila; E M Lopez-Martin; A Garcia-Pardo
Journal:  Clin Exp Immunol       Date:  2002-03       Impact factor: 4.330

5.  Chemosensitization of acute myeloid leukemia (AML) following mobilization by the CXCR4 antagonist AMD3100.

Authors:  Bruno Nervi; Pablo Ramirez; Michael P Rettig; Geoffrey L Uy; Matthew S Holt; Julie K Ritchey; Julie L Prior; David Piwnica-Worms; Gary Bridger; Timothy J Ley; John F DiPersio
Journal:  Blood       Date:  2008-12-02       Impact factor: 22.113

6.  Tie2/angiopoietin-1 signaling regulates hematopoietic stem cell quiescence in the bone marrow niche.

Authors:  Fumio Arai; Atsushi Hirao; Masako Ohmura; Hidetaka Sato; Sahoko Matsuoka; Keiyo Takubo; Keisuke Ito; Gou Young Koh; Toshio Suda
Journal:  Cell       Date:  2004-07-23       Impact factor: 41.582

7.  Changing bone marrow micro-environment during development of acute myeloid leukaemia in rats.

Authors:  B T Mortensen; P O Jensen; N Helledie; P O Iversen; E Ralfkiaer; J K Larsen; M T Madsen
Journal:  Br J Haematol       Date:  1998-07       Impact factor: 6.998

8.  Progenitor cell trafficking is regulated by hypoxic gradients through HIF-1 induction of SDF-1.

Authors:  Daniel J Ceradini; Anita R Kulkarni; Matthew J Callaghan; Oren M Tepper; Nicholas Bastidas; Mark E Kleinman; Jennifer M Capla; Robert D Galiano; Jamie P Levine; Geoffrey C Gurtner
Journal:  Nat Med       Date:  2004-07-04       Impact factor: 53.440

9.  BCR/ABL induces expression of vascular endothelial growth factor and its transcriptional activator, hypoxia inducible factor-1alpha, through a pathway involving phosphoinositide 3-kinase and the mammalian target of rapamycin.

Authors:  Matthias Mayerhofer; Peter Valent; Wolfgang R Sperr; James D Griffin; Christian Sillaber
Journal:  Blood       Date:  2002-07-18       Impact factor: 22.113

10.  Pronounced hypoxia in models of murine and human leukemia: high efficacy of hypoxia-activated prodrug PR-104.

Authors:  Juliana Benito; Yuexi Shi; Barbara Szymanska; Hernan Carol; Ingrid Boehm; Hongbo Lu; Sergej Konoplev; Wendy Fang; Patrick A Zweidler-McKay; Dario Campana; Gautam Borthakur; Carlos Bueso-Ramos; Elizabeth Shpall; Deborah A Thomas; Craig T Jordan; Hagop Kantarjian; William R Wilson; Richard Lock; Michael Andreeff; Marina Konopleva
Journal:  PLoS One       Date:  2011-08-11       Impact factor: 3.240

View more
  64 in total

1.  Role of MSC-derived galectin 3 in the AML microenvironment.

Authors:  Peter P Ruvolo; Vivian R Ruvolo; Jared K Burks; YiHua Qiu; Rui-Yu Wang; Elizabeth J Shpall; Leonardo Mirandola; Numsen Hail; Zhihong Zeng; Teresa McQueen; Naval Daver; Sean M Post; Maurizio Chiriva-Internati; Steven M Kornblau; Michael Andreeff
Journal:  Biochim Biophys Acta Mol Cell Res       Date:  2018-04-12       Impact factor: 4.739

2.  High IL-7 levels in the bone marrow microenvironment mediate imatinib resistance and predict disease progression in chronic myeloid leukemia.

Authors:  Xiaoyan Zhang; Huaijun Tu; Yazhi Yang; Qian Wan; Lijun Fang; Qiong Wu; Jian Li
Journal:  Int J Hematol       Date:  2016-06-06       Impact factor: 2.490

3.  Functional abnormalities and changes in gene expression in fibroblasts and macrophages from the bone marrow of patients with acute myeloid leukemia.

Authors:  Yu Li; Jan Dürig; Maria Göbel; Maher Hanoun; Ludger Klein-Hitpaß; Ulrich Dührsen
Journal:  Int J Hematol       Date:  2015-06-28       Impact factor: 2.490

4.  [Clinical features and prognosis of children with acute lymphoblastic leukemia and different platelet levels].

Authors:  Ao-Li Zhang; Xiao-Juan Chen; Yao Zou; Wen-Yu Yang; Ye Guo; Shu-Chun Wang; Li Zhang; Xiao-Ming Liu; Min Ruan; Tian-Feng Liu; Ben-Quan Qi; Xiao-Fan Zhu
Journal:  Zhongguo Dang Dai Er Ke Za Zhi       Date:  2019-08

5.  Antileukemia activity of the novel peptidic CXCR4 antagonist LY2510924 as monotherapy and in combination with chemotherapy.

Authors:  Byung-Sik Cho; Zhihong Zeng; Hong Mu; Zhiqiang Wang; Sergej Konoplev; Teresa McQueen; Marina Protopopova; Jorge Cortes; Joseph R Marszalek; Sheng-Bin Peng; Wencai Ma; R Eric Davis; Donald E Thornton; Michael Andreeff; Marina Konopleva
Journal:  Blood       Date:  2015-06-01       Impact factor: 22.113

6.  Understanding leukemic hematopoiesis as a complex adaptive system.

Authors:  Xavier Thomas
Journal:  World J Stem Cells       Date:  2015-10-26       Impact factor: 5.326

7.  Osteoblasts as leukemia-initiating cells.

Authors:  Benjamin J Frisch; Laura M Calvi
Journal:  Bonekey Rep       Date:  2014-09-03

Review 8.  Novel drugs for older patients with acute myeloid leukemia.

Authors:  G Montalban-Bravo; G Garcia-Manero
Journal:  Leukemia       Date:  2014-08-21       Impact factor: 11.528

9.  Enhanced Fructose Utilization Mediated by SLC2A5 Is a Unique Metabolic Feature of Acute Myeloid Leukemia with Therapeutic Potential.

Authors:  Wen-Lian Chen; Yue-Ying Wang; Aihua Zhao; Li Xia; Guoxiang Xie; Mingming Su; Linjing Zhao; Jiajian Liu; Chun Qu; Runmin Wei; Cynthia Rajani; Yan Ni; Zhen Cheng; Zhu Chen; Sai-Juan Chen; Wei Jia
Journal:  Cancer Cell       Date:  2016-10-13       Impact factor: 31.743

10.  Delineation of target expression profiles in CD34+/CD38- and CD34+/CD38+ stem and progenitor cells in AML and CML.

Authors:  Harald Herrmann; Irina Sadovnik; Gregor Eisenwort; Thomas Rülicke; Katharina Blatt; Susanne Herndlhofer; Michael Willmann; Gabriele Stefanzl; Sigrid Baumgartner; Georg Greiner; Axel Schulenburg; Niklas Mueller; Werner Rabitsch; Martin Bilban; Gregor Hoermann; Berthold Streubel; Daniel A Vallera; Wolfgang R Sperr; Peter Valent
Journal:  Blood Adv       Date:  2020-10-27
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.